INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Anavex

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Anavex Life Sciences Corporation due to significant stock losses and has set a deadline for investors to seek lead plaintiff status in a federal securities class action [1][3] Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses exceeding $75,000 in Anavex stock or options between February 1, 2022, and January 1, 2024, to contact them for legal options [1] - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [2] Group 2: Clinical Trial Results - Anavex announced positive topline results from its Phase 2b/3 clinical trial for ANAVEX®2-73 on December 2, 2022, which met primary and key secondary endpoints with statistically significant results [3] - Analysts have raised concerns about the validity of the data, suggesting that while it is provocative, it is not compelling due to the choice of statistical analyses and trial design complexities [3] - The Excellence study results announced on January 2, 2024, failed to achieve statistical significance on all but one measure, leading to a stock price drop of more than 35% [3]